Article summary
The allowed claims are expected to cover methylone-inspired benzodioxole analogues developed for potential treatment of PTSD and other psychiatric and neurological disorders. Enveric said the compounds are designed to promote neuroplasticity while reducing or eliminating hallucinogenic effects, but no clinical results were provided.
Continue to the original publication for the complete article.